Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Resfenol** is a Brazilian fixed-dose oral cold and flu medicine manufactured by Hertz. The base Resfenol products combine paracetamol, chlorpheniramine maleate, and phenylephrine hydrochloride to provide analgesic and antipyretic activity, H1-antihistamine relief of rhinorrhea and allergic symptoms, and alpha-1 adrenergic nasal decongestion. It is marketed for symptomatic treatment of influenza and the common cold, including fever, headache, myalgia, nasal obstruction, and rhinorrhea. Official product information describes capsule, oral-solution, and powder-for-oral-solution presentations. ([hertzfarma.com.br](https://www.hertzfarma.com.br/produto/resfenol/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Resfenol.